WASHINGTON – D.C.’s George Washington University School of Medicine and Health Sciences is one of four sites across the country in which a preliminary component of an experimental HIV vaccine is being given to volunteer participants in a study aimed at reversing years of failed attempts to develop an effective HIV vaccine by pursuing what study sponsors say is a new, promising approach.
The study, which involves 56 healthy, HIV-negative volunteer participants, is being conducted by the nonprofit scientific research organization known as IAVI and the biotechnology company Moderna, which developed one of the coronavirus vaccines now being used throughout the world.
In a Jan. 27 joint statement, IAVI and Moderna said their study is part of a Phase 1 trial designed to test newly developed experimental HIV vaccine antigens to determine if they will lead to the development of an effective HIV vaccine.
According to scientific literature, antigens are substances such as bacteria, viruses, and chemicals that induce the body to release antibodies that fight off infections. The statement by IAVI and Moderna says a vaccine technology developed by Moderna to use another component of the human body called messenger RNA or mRNA to strengthen a potential vaccine’s ability to fight off infection by HIV is also a part of this vaccine study.
“We are tremendously excited to be advancing this new direction in HIV vaccine design with Moderna’s mRNA platform,” Mark Feinberg, president and CEO of IAVI, says in the statement. “The search for an HIV vaccine has been long and challenging and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine,” he says in the statement.
The statement says that scientific teams at IAVI and the biotechnology firm Scripps Research helped to develop the HIV vaccine antigens being tested in the trials taking place at the GW School of Medicine and Health Sciences and at locations in Atlanta, Ga., Seattle, Wash., and San Antonio, Tex.
It says the trial involving the 56 volunteer participants — who are divided among the four sites — began on Jan. 27 and is being funded by the Bill & Melinda Gates Foundation.
Among those calling the IAVI-Moderna trial an important step in HIV vaccine development is Carl Dieffenbach, director of the Division of AIDS at the National Institute of Allergies and Infectious Diseases (NIAID), which is part of the U.S. National Institutes of Health.
“This is a variation of a theme,” Dieffenbach told the Washington Blade. “IAVI in collaboration with NIH did a version of this study already with a protein form of this immunogen,” Dieffenbach said. He said that study worked out well and was published in a scientific journal.
“What’s unique about this latest study is they’re using RNA to deliver the vaccine rather than a protein,” said Dieffenbach. “So, this is an important step for us in the vaccine field, that they can now compare the protein to the RNA.”
Dieffenbach said the IAVI-Moderna trial is taking place after two other recently completed HIV vaccine studies involving human trials that NIAID was involved in resulted in findings that the two experimental HIV vaccines were ineffective. He said a third HIV vaccine study NIAID is involved in that is taking place in the U.S. and South America is expected to be completed in about a year.
The ongoing study in the Americas involves men who have sex with men and transgender individuals as those participating in that vaccine trial, he said.
Dieffenbach said in addition to the vaccine studies, NIAID is monitoring at least two studies of medication aimed at curing HIV. One of the studies was conducted by HIV researcher Dr. Timothy Schacker, who serves as Vice Dean for research at the University of Minnesota Medical School.
Schacker arranged for human trials of people who are HIV positive and taking standard anti-retroviral HIV medication to be given an experimental HIV cure medication developed by the biotechnology company ImmunityBio called Anktiva, according to a Jan. 31 statement released by ImmunityBio.
The statement says the trials showed promising results in the ability of Anktiva to induce the immune system of HIV-positive patients under standard HIV treatment who participated in the study to “kill” the latent or “hidden” HIV in their body that would otherwise reactivate and cause illness if they stopped taking HIV medication.
The goal of the development of Anktiva is to “rid the body of the virus for good and eliminate the need for antiretroviral therapy,” the company’s statement says.
Dieffenbach said his office was also monitoring an HIV cure study being conducted by the Rockville, Md., based genetic engineering company called American Gene Technologies. The company is conducting a human trial for a therapeutic treatment it has developed that’s intended to enable the immune system of HIV-positive people to permanently eliminate HIV from their bodies. The company has said it was hopeful that early results of the effectiveness of the treatment would become available this year.
President’s Emergency Plan for AIDS Relief marks year 20
Achievements PEPFAR have been remarkable, well-documented by outside evaluators, and hugely applauded throughout the advocacy community
WASHINGTON – The President’s Emergency Plan for AIDS Relief (PEPFAR) marks its twenty year anniversary today, marking the largest commitment by any nation to address a single disease in the world.
The initiative which was personally led and launched by former President George W. Bush in 2003, its funding has totaled more than $110 billion to date, including funding for the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), to which the U.S. government is the largest donor.
PEPFAR is credited with saving millions of lives and helping to change the trajectory of the global HIV epidemic. The White House today released a statement by President Joe Biden marking the 20th Anniversary:
Twenty years ago today, President George W. Bush declared that preventing and treating HIV/AIDS was a foreign policy priority of the United States. At a time when nearly 30 million people were HIV positive, but very few were receiving life-saving medicines, the President’s Emergency Plan for AIDS Relief (PEPFAR) transformed the global AIDS response and laid a marker for America’s commitment to countries that were impacted the hardest by the AIDS epidemic. Helping lead the bipartisan effort in Congress to authorize PEPFAR is among my proudest achievements from my time in the Senate. To this day, PEPFAR remains a powerful example of America’s unmatched ability to drive progress and make life better for people around the world.
Since 2003, PEPFAR has saved more than 25 million lives and dramatically improved health outcomes in more than 55 partner countries. AIDS-related deaths have declined by 68 percent since their peak in 2004, and new HIV infections are down 42 percent. PEPFAR investments have ensured that 5.5 million babies have been born HIV-free. And two decades of investment in partner nations’ health systems played a critical role in countries’ ability to respond to other health crises such as COVID-19, Mpox, and Ebola.
Today, PEPFAR continues to support 20.1 million people around the world with HIV/AIDS treatment, and my Administration is committed to continuing to lead the global HIV/AIDS response. We will build on our decades of progress to reach the Sustainable Development Goal of ending AIDS by 2030, work to eliminate the stigma and inequities that keep people from accessing care, and keep the voices of people living with HIV/AIDS at the center of our response. I look forward to working with Congress on PEPFAR’s reauthorization this year.
PEPFAR is overseen by the U.S. Global AIDS Coordinator, who is appointed by the President, confirmed by the Senate, and reports directly to the Secretary of State, as established through PEPFAR’s authorizing legislation.
PEPFAR’s original authorization established new structures and authorities, consolidating all U.S. bilateral and multilateral activities and funding for global HIV/AIDS. Several U.S. agencies, host country governments, and other organizations are involved in implementation.
Dr. John Nkengasong, the current coordinator was sworn in on June 13, 2022, and holds the rank of Ambassador leading the Office of the Global AIDS Coordinator (OGAC) at the U.S. Department of State.
Twenty years ago this month, President George W. Bush announced #PEPFAR during his State of the Union address. Since then, the U.S. government has invested $100B+ in the global HIV/AIDS response through PEPFAR, saving 25M lives & bringing us closer to #EndAIDS2030. #PEPFAR20 pic.twitter.com/SMAOHWPZ03— PEPFAR (@PEPFAR) January 11, 2023
Nobel Prize winning scientist Harold Varmus, who served as Director of the National Institutes of Health (NIH) from 1993 to 1999 and currently the Lewis Thomas University Professor of Medicine at Weill Cornell Medicine in New York City, wrote in an article honoring World Aids Day 2013:
[…] “the PEPFAR story must begin with George W. Bush and his wife, Laura, and their interests in AIDS, Africa, and what Bush termed “compassionate conservatism.” According to his 2010 memoir, Decision Points, the two of them developed a serious interest in improving the fate of the people of Africa after reading Alex Haley’s Roots and visiting The Gambia in 1990.3 In 1998, while pondering a run for the U.S. presidency, he discussed Africa with Condoleezza Rice, his future secretary of state; she said that, if elected, working more closely with countries on that continent should be a significant part of his foreign policy. She also told him that HIV/AIDS was a central problem in Africa but that the United States was spending only $500 million per year on global AIDS, with the money spread across six federal agencies, without a clear strategy for curbing the epidemic.”
Key Facts (As provided by Kaiser Health & Family Foundation)
- Although the U.S. has been involved in efforts to address the global AIDS crisis since the mid-1980s, the creation of the President’s Emergency Plan for AIDS Relief (PEPFAR) in 2003 marked a significant increase in funding and attention to the epidemic.
- PEPFAR is the largest commitment by any nation to address a single disease in the world; to date, its funding has totaled more than $110 billion, including funding for the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), to which the U.S. government is the largest donor. PEPFAR is credited with saving millions of lives and helping to change the trajectory of the global HIV epidemic.
- U.S. funding for PEPFAR grew from $2.2 billion in FY 2004 to $7.0 billion in FY 2022; FY 2022 funding includes $5.4 billion provided for bilateral HIV efforts and $1.6 billion for multilateral efforts ($50 million for UNAIDS and $1.56 billion for the Global Fund).
- As the COVID-19 pandemic continues to have profound effects across the world, PEPFAR has acted to respond to COVID-19 in countries that receive support in order to minimize HIV service disruptions and leverage the program’s capabilities to address COVID-19 more broadly.
- Looking ahead, PEPFAR faces several issues and challenges, including how best to: address the short- and long-term impacts of COVID-19 on PEPFAR and the HIV response; accelerate progress toward epidemic control in the context of flat funding; support and strengthen community-led responses and the sustainability of HIV programs; define its role in global health security and broader health systems strengthening efforts; and continue to coordinate with other key players in the HIV ecosystem, including the Global Fund.
Key Activities and Results (As provided by Kaiser Health & Family Foundation)
PEPFAR activities focus on expanding access to HIV prevention, treatment, and care interventions. These include provision of antiretroviral treatment, pre-exposure prophylaxis, voluntary male circumcision, condoms, and other commodities related to HIV services. In addition, PEPFAR has launched specific initiatives in key strategic areas. For example, in 2015, PEPFAR launched DREAMS, a public-private partnership that aims to reduce HIV infections in adolescent girls and young women.
The latest results reported by PEPFAR indicate that it has:
- supported testing services for 63.4 million people in FY 2021;
- prevented 2.8 million babies from being born with HIV, who would have otherwise been infected;
- provided care for more than 7.1 million orphans and vulnerable children (OVC);
- supported training for nearly 300,000 new health care workers; and
- supported antiretroviral treatment for 18.96 million people.
- In the 15 countries implementing the DREAMS initiative, new diagnoses among adolescent girls and young women have declined with most DREAMS areas (96%) experiencing declines greater than 25% and nearly two-thirds with declines greater than 40%.
The achievements of the PEPFAR program have been remarkable, well-documented by outside evaluators, and hugely applauded throughout the advocacy community and the developing world. In general, milestones have been met, the program has been enlarged (for instance, to include some research on implementation of medical assistance), the roster of PEPFAR countries has grown and spending plans have not been exceeded.
FDA eases blood donation restrictions for gay & bisexual men
The FDA’s proposal would lift the mandatory three-month deferral period for some men who have sex with men
SILVER SPRING, Md. – The U.S. Food and Drug Administration (FDA) introduced a proposed change to its blood donation guidelines on Friday that would ease restrictions for gay and bisexual men.
The FDA notes the proposal, news of which was first reported in November, would bring U.S. policies in alignment with those in place in countries like the U.K. and Canada. The agency is expected to formally adopt the new guidelines after a public comment period.
The move follows criticism from LGBTQ groups and organizations like the American Medical Association (AMA) who have long argued the current policy is homophobic and based on an outdated understanding of the risks associated with blood donation by men who have sex with men.
As the AMA wrote of the current policy: “a man who has protected sex with another man in the three months prior to a blood donation cannot be a donor, but a man or woman who has unprotected sex with multiple partners of the opposite sex over the same time period remains eligible.”
The FDA’s proposal would lift the mandatory three-month deferral period for some men who have sex with men and instead use a “gender-inclusive, individual risk-based questions relevant to HIV risk.”
Potential donors would be asked for information about their sexual history over the past three months. Respondents who indicate they have had sex with one or more new sexual partners would then be asked whether they have had anal sex during this period. Those who answer “yes” would be deferred from blood donation.
Axios noted that as of this morning, about 20 percent of the country’s community blood centers have a one-day supply or less, while the FDA’s broadened eligibility criteria would increase the annual blood supply by two to four percent, citing data from America’s Blood Centers’ daily tracker and the Williams Institute.
U.S. Sen. Tammy Baldwin (D-Wis.) issued a statement celebrating the FDA’s proposal. “As I have long advocated for, this blood donation policy takes a step forward and is better rooted in the most up-to-date science with a focus on individual risk factors, not outdated stigmas that effectively ban gay and bisexual men,” she said.
Baldwin has repeatedly urged the agency to revisit its blood donation policy over the years, including by corralling support from other members of Congress to cosign letters to the FDA in 2014 and 2016, raising the issue again in 2020 as the COVID-19 pandemic exacerbated shortages in the blood supply.
The Congressional LGBTQ+ Equality Caucus also acknowledged the move in a statement by its chair, Rep. Mark Pocan (D-Wis.): “I am glad the FDA is finally moving toward an individual risk-based assessment model, but recognize, based on existing reporting, that many LGBTQI+ people may still be barred from donating,” he said. “I look forward to taking a closer look at the proposed guidelines once they are published and working with the FDA to ensure that any unnecessary barriers are removed.”
Several LGBTQ groups also issued statements celebrating the FDA’s new guidance.
“These changes are 40-plus years in the making, and are a tremendous leap forward toward elevating science over stigma,” said GLAAD President Sarah Kate Ellis. “GLAAD and leading medical experts have long been advocating for guidelines that see and treat LGBTQ people the same as any other person, including as potential donors who want to help others.”
“This new policy removes a decades-long barrier for many in our community – and there is more to do to ensure gay, bisexual and transgender people are no longer unfairly stigmatized when they try to donate blood,” Human Rights Campaign President Kelley Robinson said. “The assessment criteria have flaws, focusing excessively, for instance, on the number of partners a potential donor has instead of just on new partners,” she added.
Carl Schmid, executive director of the HIV+ Hepatitis Policy Institute, said: “While this long-overdue change is being made based on the science and the facts, which have been clear for years, it is the result of the leadership of the Biden administration that continues to tear down discriminatory government policies.”
Experimental HIV vaccine failure, deemed safe but ineffective
“We remain steadfast in our commitment to advancing innovation in HIV & hope the data from Mosaico will provide insights for future efforts”
BETHESDA, Md. – A clinical trial of an investigational HIV vaccine regimen, being conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID) by Janssen Pharmaceutical Companies and global partners of parent company Johnson & Johnson dubbed “Mosaico,” was discontinued.
In an announcement made Wednesday, NIAID said the HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board had determined.
A spokesperson for Johnson & Johnson noted in light of the board’s determination, the Mosaico clinical trial will be discontinued. Participant notifications and further analyses of the data are underway. Throughout the trial, study investigators have ensured that any individuals who contracted HIV received prompt HIV treatment and care.
Both Johnson & Johnson and NIAID stressed that no safety issues with the vaccine regimen were identified.
“We are disappointed with this outcome and stand in solidarity with the people and communities vulnerable to and affected by HIV,” said Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC. “Though there have been significant advances in prevention since the beginning of the global epidemic, 1.5 million people acquired HIV in 2021 alone, underscoring the high unmet need for new options and why we have long worked to tackle this global health challenge. We remain steadfast in our commitment to advancing innovation in HIV, and we hope the data from Mosaico will provide insights for future efforts to develop a safe and effective vaccine. We are grateful to our Mosaico partners and the study investigators, staff and participants.”
Janssen Vaccines & Prevention sponsored the Mosaico study with funding support from NIAID, part of the National Institutes of Health. The trial was conducted by the NIAID-funded HIV Vaccine Clinical Trials Network, based at the Fred Hutchinson Cancer Research Center in Seattle. The U.S. Army Medical Research and Development Command provided additional study support.
The Phase 3 Mosaico Study:
Mosaico, a Phase 3 study of Janssen’s investigational HIV vaccine regimen, began in 2019, and completed vaccinations in October 2022. The study included approximately 3,900 cisgender men and transgender people who have sex with cisgender men and/or transgender people, who represent groups and populations vulnerable to HIV, at over 50 trial sites in Argentina, Brazil, Italy, Mexico, Peru, Poland, Puerto Rico, Spain and the United States.
The study evaluated an investigational vaccine regimen containing a mosaic-based adenovirus serotype 26 vector (Ad26.Mos4.HIV) administered during four vaccination visits over one year. A mix of soluble proteins (Clade C/Mosaic gp140, adjuvanted with aluminum phosphate) was also administered at visits three and four.
The Mosaico DSMB analysis, based on the data available to date, indicated that the regimen does not protect against HIV and the study is not expected to meet its primary endpoint. No safety issues with the vaccine regimen were identified. In light of this, the study will be discontinued, and further analyses are underway.
Patti LaBelle, Gladys Knight dazzle World AIDS Day concert
“As millions remain affected by HIV/AIDS, World AIDS Day provides an opportunity to honor those we’ve lost and those living with HIV/AIDS”
WASHINGTON – The AIDS Healthcare Foundation (AHF) hosted its 2022 World AIDS Day Concert on Wednesday, Nov. 30, in the concert hall of The John F. Kennedy Center for the Performing Arts in the nation’s capital.
Renowned multi-Grammy Award-winning vocalists Patti LaBelle and Gladys Knight delivered show-stopping performances to the packed crowd, which included supporters, dignitaries such as: Harold Phillips, Director of the White House Office of National AIDS Policy; White House Senior Advisor for Public Engagement, Mayor Keisha Lance Bottoms, Congresswoman Sheila Jackson Lee, and New Orleans Mayor, Mayor LaToya Cantrell, and more, in a night of hope and celebration.
AIDS Healthcare Foundation (AHF), is the world’s largest HIV/AIDS care provider, currently operating in 45 countries. The concert is held every year to commemorate World AIDS Day, observed internationally each year on Dec. 1. This year also marked the global organization’s 35th anniversary.
At the event, longtime humanitarian and AIDS advocate, Princess Diana was honored, posthumously, with AHF’s Lifetime Achievement Award. Under its “Keep the Promise!” banner, AHF also acknowledged progress made in the global fight against HIV and AIDS and continues to raise awareness about “The Other Pandemic” as a reminder of the significant work still to be done on HIV/AIDS, as well as remembering the lives that have been lost over the years.
Michael Weinstein, President of AHF, said, “As millions remain affected by HIV/AIDS around the globe, World AIDS Day annually provides an opportunity to honor those we’ve lost and those living with HIV/AIDS today, as well as reminding leaders and the community of the work that still remains to address this epidemic. From providing compassionate AIDS hospice care in those darkest early days to growing to become the largest global AIDS organization today, now providing lifesaving care and treatment to more than 1.7 million people around the globe, we also celebrate the tireless work of all those who help make today’s AHF possible: our staff, Board, affiliate organizations and affinity groups, friends, family and elected officials and community partners across the globe, but most of all, our clients and patients—with our annual 2022 World AIDS Day event. It was a momentous night to host our World AIDS Day concert at The Kennedy Center for the first time, and welcome back the legendary Patti LaBelle, and have another great American icon, Gladys Knight join us, while also being able to honor the legacy and humanitarian work of the late Princess Diana.”
Cleve Jones, activist & founder of AIDS Memorial Quilt honored
National AIDS Memorial hosted observances at the 10-acre Memorial Grove and displaying Quilt in nearly 100 communities throughout the U.S.
SAN FRANCISCO – The National AIDS Memorial marked World AIDS Day with a national observance at the 10-acre National AIDS Memorial Grove in San Francisco, honoring AIDS activist and founder of the AIDS Memorial Quilt Cleve Jones with its Lifetime of Commitment Award.
The two days of events brought together leaders on the front lines of the epidemic for powerful conversations and events focused on “Changing the Pattern for a Future without AIDS,” referencing a major initiative of the Memorial that is bringing the Quilt to the South to address the growing crisis of rising HIV rates amount communities of color and marginalized populations.
Jones, who founded the Quilt thirty-five years ago, was recognized for his visionary leadership, activism, and powerful voice in the fight for health and social justice. He remains an inspirational force for change and action today, standing up without hesitation and using his voice for those who are often overshadowed and not heard.
U.S. House Speaker, Rep. Nancy Pelosi (D-Cailf.) praised Jones in a special video tribute, saying, “Cleve, you are a force of nature – unshakable in the face of adversity, overflowing with a passion for serving others.”
“When the AIDS crisis tightened its grip on San Francisco – when pain and despair grew rampant – you kept hope alive,” she continued. “You were a shining light in the dark, building community out of grief and spurring action out of anguish. From the halls of power to union halls and picket lines, you have never relented in your mission: empowering the oppressed, tearing down injustice and honoring the dignity and beauty of every person.”
Presenting the award to Jones was former San Francisco mayor and mentor Art Agnos to an audience of more than 600 people from the community who gathered on the eve of World AIDS Day for a gala to support the Memorial’s programs.
“I’m honored to receive this award, but more importantly I’m so pleased that the Quilt now has a permanent home with the National AIDS Memorial and that it is continuing its mission of activism and justice. One thing I’ve learned is that through hope one finds courage and through courage we find love. Love is at the core of what we do and that is what this Quilt represents,” Jones told the audience gathered.
The National AIDS Memorial worked with local partners from across the country to display hundreds of Quilt sections featuring more than 3,500 individual panels in nearly 100 communities on World AIDS Day.
The largest Quilt display ever in Alabama is taking place in Montgomery and surrounding areas as part of the memorial’s Change the Pattern initiative. The program, funded through a $2.4 million grant from Gilead Sciences, is organizing quilting workshops, displays and educational programming with Southern AIDS Coalition throughout the Southern U.S.
“On this World AIDS Day, it is inspiring to know that thousands of Quilt panels are on display in communities across the country, touching hearts and minds through the stories represented in the fabric,” said Gilead Sciences Chairman and CEO Daniel O’Day. “The Quilt’s purpose remains as strong and important today, as it was thirty-five years ago, when the vision of Cleve Jones sparked a powerful movement to advance health and social justice.”
The National AIDS Memorial’s World AIDS Day Observance panelists highlighted the importance of the work being done around the country, the interconnectivity of issues to reach zero, and the importance of education and outreach to at-risk populations during three powerful conversations available for viewing online on the memorial’s website and include: Reflections with Cleve Jones and 35 years of the Quilt; The State of the Epidemic Today with Leaders on the Frontlines; and Young Leaders Making an Impact.
“As our community comes together this World AIDS Day, it’s hard not to look around and see who’s missing – our friends, lovers, and family we’ve lost over four decades of this horrific, cruel disease,” said National AIDS Memorial CEO John Cunningham. “It always brings tears, and we carry so many emotions, particularly as we think of what could have been. But for me, as a man living with HIV/AIDS, I shift to a brighter space, choosing to look around me, thinking about so many of us still here, living and thriving. Survivors, who have so much to be thankful for, but also a heavy burden to share our own stories and journey, so history never repeats itself.”
He continued, “Today, people are still dying and there should have been a cure long ago. We are angry because bigotry, hate, and stigma persist today in society. And we carry shame, because communities of color and marginalized populations continue to be disproportionately impacted by HIV and discrimination, and it shouldn’t be this way. It’s time to change the pattern.”
Translatinx network helps a resilient community ‘Live Its Truth’
“We’re trying to push ourselves to the next level through community empowerment and leadership development”
NEW YORK – When Cristina Herrera was 15 years old, she traveled alone from Southern California to the Bronx in pursuit of new life experiences. A native of El Salvador, Cristina thought as a teenager that she was different, but she was unsure about which terminology fully captured her identity.
“I knew that I wasn’t gay,” explains Cristina. “But I couldn’t put into words as to who I was.”
It was only through connecting with the trans Latinx community in New York that Cristina found herself – and came out as transgender.
When Cristina began her gender transition in the mid-1980s, she says there were barely any employment opportunities for a transgender person. To survive, many immigrant trans women in Cristina’s circle engaged in sex work and became more susceptible to contracting HIV. Policing and arrests of sex workers also put their immigration statuses in peril, and stigma exposed them to violence. It was during this time that Cristina became set on improving the lives of trans Latinx people.
“My community was already informally supporting one another,” she says. “But I wanted to make sure that other people would never have to go through some of the difficult issues I experienced.”
Determined to fulfill this promise, Cristina put herself through college and landed a job at a nonprofit supporting the LGBTQ+ community. She absorbed as much as she could at the organization, but she started to want a bigger influence on how to serve the community that helped find her identity.
“In 2005, I began dreaming about starting a trans-led, immigrant-led organization,” she says. “My dream came true two years later when I started the nonprofit.”
Today, as the founder and CEO of the advocacy nonprofit Translatinx Network, she serves trans Latinx people in New York City and beyond. The organization, which for the past three years has been a Gilead TRANScend Community Impact Fund grantee, connects people to legal aid, HIV prevention and support groups, and immigration assistance.
In the years since its creation, Cristina and her colleagues have led the charge in providing support and connections for trans Latinx people as they build their communities in the United States.
“Many people in our community went from being in the shadows to becoming documented and getting their green cards or work permits,” she says. “We were showing our community that we don’t have to be stuck – that there’s more to life.”
Cristina is now looking for ways to replicate the success of the organization by gathering information and its outcomes and continuing to expand its services. “We want to stay on the front lines and keep our community healthy and protected,” she says. “We’re trying to push ourselves to the next level through community empowerment and leadership development.”
And Cristina is proud that through her organization’s success, she’s able to serve a population that has historically been left out or forgotten.
“I love any opportunity where I can be there for others,” she says. “I want all of us to be able to live our truth while at the same time fulfill our life goals.”
Ending HIV-related stigma in the Southern U. S.: Gina’s story
“Stigma is an onion with many layers,” Gina says. “We can really do this – we really can, but we have to address the layers that drive HIV”
BIRMINGHAM, Al. – Gina Brown has been living with HIV for 27 years and introduces herself as a social worker by training, but an activist by birth. As the Director of Strategic Partnerships and Community Engagement at the Southern AIDS Coalition, she’s working to fight against challenges that she has personally experienced such as homelessness, addiction and abuse, as well as stigma, racism, sexism and ageism.
“Everything that you could think of when it comes to HIV, I’ve experienced,” she says. “When I’m sitting at the table, I’m not just talking with an employee hat on. I’m talking from a community standpoint as a person on the same journey.”
Stigma can be a significant barrier to receiving HIV care or medical treatment. A 2021 survey by GLAAD and Gilead shows that the U.S. South not only has the highest rates of HIV diagnosis, but it’s also a region that is generally uncomfortable with HIV. Positive test results, in turn, are too often accompanied by secrecy and isolation.
“Stigma kills. I know that sounds like a cliché, but it’s the truth,” Gina says. “It keeps people out of care. It keeps people from taking their medication. It keeps people from disclosing their status. It keeps people from being happy.”
Stigma impacts people everywhere with HIV, but Gina believes in the Southern United States it’s more than just external stigma. “We internalize what people say and think about us. We get caught up in it and actually think those things about ourselves too.”
The Southern AIDS Coalition, a Gilead grantee, focuses on stigma reduction and culturally appropriate care. Education and public health advocacy are core to the organization’s goals of preventing new transmissions and building a better life for people living with HIV.
Using deliberate language to discuss HIV is one important tool the coalition uses to help dismantle stigma, Gina says.
“You go in the room, and you might have somebody who will stand up and say, ‘I’m HIV.’ And I say, ‘No, you’re living with HIV.’ That’s the first thing, getting people to understand that we are living, we’re not dying, we’re not sick, we’re not all of those things,” she says.
Power of Community: Sharing HIV Experiences
Gina also helps facilitate a program called “Out of the Shadows,” with the Institute of Women and Ethnic Studies. The group works to provides a safe space for women in the New Orleans community to share their HIV experiences, improve access to services and overcome feelings of isolation. She says it was her own experience with the community that was critical to helping her regain her confidence after being diagnosed.
“What you see now is not always who I was in this fight. It was people who truly carried me and gave me tools to empower myself. People saw things in me that I never saw in myself,” she says.
Gina now wants to serve as that type of person for those she works with, and she always strives to meet them where they are in their journeys. “If you need to crawl, I will crawl with you. When you start walking, I will walk with you.”
But Gina says with a laugh, “When you start running, you’re on your own because I’m too old to run. I’ll do everything else with you, but I’m not running.”
Ending the HIV Epidemic
Efforts by the Southern AIDS Coalition and other organizations to reduce stigma and discrimination have been highlighted by the United Nations as critical to ending the epidemic. Gina looks with optimism toward the end of the epidemic and the UNAIDS goal to get every community and country on track to end AIDS as a public health threat by 2030.
“Stigma is an onion with many layers,” Gina says. “We can really do this – we really can, but we have to address the layers that drive HIV.”
Iconic landmarks in Los Angeles to light up red on World AIDS Day
This year’s theme, “Putting Ourselves to the Test: Achieving Equity to End HIV,” calls out the disproportionate impact across sub-populations
LOS ANGELES – As Angelenos mark World AIDS Day, several prominent landmarks around Los Angeles County– including Union Station, City Hall/Grand Park Fountain, Dignity Health Sports Park, LAX Pylons, and Six Street Viaduct — will switch their evening architectural lighting to all red to increase awareness about HIV/AIDS, show solidarity in the fight against HIV, and honor those who have died due to HIV disease.
World AIDS Day, observed each year on December 1, provides the opportunity to honor and remember the more than 40 million people worldwide, including over 27,000 Los Angeles County (LAC) residents lost to HIV/AIDS since this epidemic began.
This year’s World AIDS Day theme, “Putting Ourselves to the Test: Achieving Equity to End HIV,” calls attention to the disproportionate impact of HIV across sub-populations, particularly across race, gender, sexual orientation and geographic lines.
Los Angeles County has an estimated 59,400 people living with HIV and in 2021 there were 1,479 new HIV diagnoses reported, mostly among gay men, African-Americans, Latinos, and transgender persons.
“We thank our partners across the community who have been working for decades to increase awareness and prevention of HIV/AIDS and provide services and support for those living with HIV, “and honor those in our communities we lost to this terrible disease,” said Barbara Ferrer, PhD, MPH, MEd, Director of Public Health. “More than anything, as we honor, on World AIDS Day, those in our communities we lost to this terrible disease, we re-commit ourselves to the work to end the HIV/AIDS epidemic, which continues to disproportionately impact communities of color and the LGBTQ community.”
Public Health works with others to help bring an end to the epidemic by reducing the number of new annual HIV infections, decreasing the number of undiagnosed people living with HIV, and increasing the viral suppression rates among people who are diagnosed with HIV.
Public Health collaborates with a broad cross-section of diverse community partners to implement community-driven outreach and education, community-based HIV/STD testing, linkage to care, intensive street-based case management, and clinic-based services. Recently, Public Health has spearheaded innovative programming through our many new Ending the HIV Epidemic (EHE) Initiatives (www.lacounty.hiv), expanded HIV testing access through both community-based partners and the www.takemehome.com testing initiative, ongoing efforts to prevent homelessness among persons living with HIV; enhanced outreach efforts to the transgender community through our TransInLA Instagram and Facebook pages and supporting HIV-positive individuals with accessing lifesaving medication. Research shows that suppressing HIV to undetectable levels virtually eliminates transmission of the virus to sexual partners.
Public Health encourages people to learn more about HIV, know their HIV status, and, if necessary, access free life-saving HIV medications and services. To learn more about HIV and STDs and locate HIV testing, services, and resources, please visit www.getprotectedla.com and http://publichealth.lacounty.gov/dhsp/.
GLAAD study: Signs of progress in efforts to combat HIV stigma
Some of the conclusions from GLAAD’s study have broader applicability to the stigmatization of other diseases and health conditions
NEW YORK – A welcome sign that some progress has been made in efforts to combat stigma, data from a forthcoming study by GLAAD found that Americans have become increasingly comfortable interacting with people who are living with HIV.
GLAAD, the largest LGBTQ media advocacy organization, shared an advance copy of its 2022 State of HIV Stigma Study with the Washington Blade ahead of its release Thursday during World AIDS Day.
The study’s documentation of the substantial increase in the percentage of respondents who said they would feel comfortable interacting with people living with HIV — up from 36 percent in 2020 to 43 percent this year — was hardly the only metric pointing to possible improvements with respect to the stigmatization of HIV in America.
At the same time, other findings in the report present a grimmer picture. As GLAAD President Sarah Kate Ellis said in a statement, the data underscores the need to “dramatically accelerate public health messaging about HIV and visibility about HIV in the media for it to be understood as the treatable, untransmittable and preventable condition it is.”
Ninety percent of respondents said they believe stigma around HIV persists, Ellis noted. And GLAAD’s study offers some insight into how and why, looking at a variety of different types of evidence.
For example, it documents the prevalence of false and medically inaccurate beliefs about how and to whom the virus is transmitted (revealing that fewer people now believe “only certain groups of people get HIV.”) It assesses the extent to which respondents saw stories in the media about people living with HIV (with only one in three reporting that they had.) And it provides some insight into the relative efficacy of public health messaging around risk reduction strategies (a good sign: Knowledge about the use of pre-exposure prophylaxis for the prevention of HIV has increased.)
Some of the conclusions that can be gleaned from GLAAD’s study have broader applicability to the stigmatization of other diseases and health conditions.
Last month, the group published a summary of its qualitative interviews on stigma, writing: “We heard people mention a few similarities between COVID-19 and HIV as it relates to the stigma that both viruses carry, much of it centered around an initial lack of education, and fear of transmission.”
As Ellis said in her statement about the forthcoming study, “Newly-released data show how stigma, inadequate resources and lack of comprehensive public health messaging set back the fight against HIV during the COVID-19 pandemic and delayed response to the monkeypox virus (mpox) outbreak this year.”
GLAAD has published annual State of HIV Stigma Studies since 2020, a project that is funded by Gilead’s COMPASS initiative. The report can be found on the group’s End HIV Stigma page, with a downloadable PDF available here.
Biden outlines plan to renew fight against HIV/AIDS
Biden on the eve of World AIDS Day outline ways his administration will fight the HIV/AIDS epidemic in the U.S. & globally
WASHINGTON – President Joe Biden detailed how his administration plans to improve the lives and health outcomes for people living with HIV/AIDS while strengthening treatment and prevention efforts at home and abroad in a statement published Wednesday on the eve of World AIDS Day.
Proposed healthcare reforms on the domestic agenda included improving access to lifesaving treatments, broadening the use of preexposure prophylaxis (PrEP) to reduce the rate of new infections, and strengthening efforts to reduce stigma associated with the disease. Biden noted his request for $850 million from Congress to fund these initiatives.
Policy wise, he highlighted the administration’s pressure on the Armed Forces to sunset rules prohibiting deployments and commissions for servicemembers with HIV, and on state legislatures to repeal HIV criminalization statutes used to prosecute people for exposing others to HIV.
Internationally, the president said, “My administration has also pledged up to $6 billion to the Seventh Replenishment of the Global Fund to Fight AIDS, Tuberculosis, and Malaria — an initiative that has saved an estimated 50 million lives to date.” He called on other countries to match the pledge “so we can together deliver on the promise of health and well-being for millions around the world.”
“World AIDS Day presents an opportunity to renew America’s commitments to fighting the disease,” Biden said, while also acknowledging the tremendous progress in science, medicine, public health, and other arenas that have made the prospect of an end to AIDS and the worldwide transmission of HIV achievable. “At the same time, while these advancements have saved so many lives, they also exposed longstanding racial and gender-based disparities in access to prevention and care.”
“For the more than 38 million people around the world now living with HIV — especially members of the LGBTQI+ community, communities of color, women, and girls — a diagnosis is still life-altering,” Biden said. “We can do better.”
“As we today honor the 700,000 Americans and 40 million lives lost worldwide to AIDS-related illnesses over the years, we have new hope in our hearts,” the president’s statement concludes. “We finally have the scientific understanding, treatments, and tools to build an AIDS-free future where everyone — no matter who they are, where they come from, or whom they love — can get the care and respect they deserve.”
The full statement is available here.
Sign Up for Blade eBlasts
Rachel Levine tackles bad info on Covid & gender-affirming care
Calling unseen LGBTQ playwrights, This could be your big break!
Newsom calls for Federal investigation of high Natural Gas prices
Knott’s Berry Farm is planning to hire 2,500 seasonal employees
Victory Institute urges Senate to confirm Gigi Sohn for FCC
Calif. bill to strengthen penalties for Fentanyl trafficking introduced
Jacob Caswell is 1st-Ever Nonbinary Runner of the year
Walsh: Doctors providing gender-affirming care should be executed
Trans Gen Z er dies after wait on UK Healthcare system
Rabbi & 11-year-old son testify against anti-trans legislation
Fentanyl Crisis4 days ago
Calif. bill to strengthen penalties for Fentanyl trafficking introduced
Sports3 days ago
Jacob Caswell is 1st-Ever Nonbinary Runner of the year
News Analysis4 days ago
Walsh: Doctors providing gender-affirming care should be executed
United Kingdom4 days ago
Trans Gen Z er dies after wait on UK Healthcare system
Missouri3 days ago
Rabbi & 11-year-old son testify against anti-trans legislation
U.S. Federal Courts4 days ago
Newsom on federal court allowing domestic violence abusers guns
European Union4 days ago
Finland to allow Transgender people to change gender without sterilization
Features3 days ago
Frequent social media use may change young teens’ brains
Health4 days ago
White House ‘walking the walk’ on LGBTQ public health
Southern California4 days ago
Triple A: Gas prices move up slightly, but more increases expected